Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37

Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD

Pfizer announced complete results from a Phase 3, 12-week, pivotal study in patients aged 12 and older with moderate to severe atopic dermatitis. Abrocitinib, an investigational oral Janus kinase 1 inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to placebo. Safety data showed that both evaluated doses of abrocitinib were well tolerated and were consistent with a companion study from the JAK1 Atopic Dermatitis Efficacy and Safety global development program. The co-primary study endpoints in JADE MONO-1 were the proportion of patients who achieved an Investigator Global Assessment score of clear or almost clear skin and two-point or greater improvement relative to baseline; and the proportion of patients who achieved at least a 75% or greater change from baseline in their Eczema Area and Severity Index score. The key secondary endpoints were the proportion of patients achieving a four-point or larger reduction in itch severity measured with the pruritus numerical rating scale, and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis, a patient-reported measurement scale developed by Pfizer. Other secondary endpoints included the proportion of patients who achieved a 90% or greater change in EASI score, and the percentage change from baseline in their SCORing Atopic Dermatitis response at all scheduled time points. Both doses of abrocitinib significantly improved the IGA and EASI-75 dose response outcomes compared to placebo. The percentage changes in SCORAD were significantly greater at all time points in the 200mg and 100mg treatment arms compared to placebo.

  • 29

    Oct

  • 06

    Nov

PFE Pfizer
$36.11

0.31 (0.87%)

10/07/19
10/07/19
UPGRADE
Target $25

Outperform
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the partnership of AKCEA-ANGPTL3-Lrx with Pfizer (PFE) for development in cardiovascular and metabolic disease indications. The analyst views the partnership as validating of the ANGPTL3 opportunity, with terms "highly favorable" to Akcea, significant market opportunity in NAFLD/NASH/CVD and upfront cash supportive of increased investment in TEGSEDI commercialization, preparation for TTR-LICA and externally focused business development. Birchenough also raised his price target on Akcea's shares to $25 from $24.
10/07/19
STFL
10/07/19
NO CHANGE
Target $31
STFL
Hold
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
Stifel analyst Paul Matteis called Akcea Therapeutics' (AKCA) licensing agreement for AKCEA-ANGPTL3-LRx with Pfizer (PFE) a "solid and unexpected win" for the former in the wake of recent management turnover. Pfizer will pay up to $1.3B in milestones, including $250M in cash upfront, noted Matteis, who does not think investors were ascribing "all that much credit" to this asset. Matteis has a Hold rating on Akcea shares with a $31 price target.
10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.

TODAY'S FREE FLY STORIES

AAPL

Apple

$263.19

-3.13 (-1.18%)

, SPX

S&P 500

$0.00

(0.00%)

17:35
11/20/19
11/20
17:35
11/20/19
17:35
Periodicals
Trump says considering whether to exempt Apple from China tariffs, Reuters says »

U.S. President Donald…

AAPL

Apple

$263.19

-3.13 (-1.18%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$216.91

-1.26 (-0.58%)

17:28
11/20/19
11/20
17:28
11/20/19
17:28
Hot Stocks
Raytheon awarded $386M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLH

Red Lion Hotels

$3.36

0.015 (0.45%)

17:23
11/20/19
11/20
17:23
11/20/19
17:23
Syndicate
Breaking Syndicate news story on Red Lion Hotels »

Red Lion Hotels files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KZIA

Kazia Therapeutics

$7.40

4 (117.65%)

17:20
11/20/19
11/20
17:20
11/20/19
17:20
Hot Stocks
Breaking Hot Stocks news story on Kazia Therapeutics »

Kazia Therapeutics Ltd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$30.05

0.13 (0.43%)

17:14
11/20/19
11/20
17:14
11/20/19
17:14
Syndicate
Invitation Homes announces offering of 57.6M shares of common stock for holders »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVV

Universal Corporation

$50.73

-0.84 (-1.63%)

17:08
11/20/19
11/20
17:08
11/20/19
17:08
Hot Stocks
Universal Corporation to acquire FruitSmart, terms not stated »

Universal Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.02

0.99 (3.66%)

17:06
11/20/19
11/20
17:06
11/20/19
17:06
Hot Stocks
Breaking Hot Stocks news story on Uber »

Uber up 2.1% or 59c at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

SBLK

Star Bulk Carriers

$10.04

-0.12 (-1.18%)

17:03
11/20/19
11/20
17:03
11/20/19
17:03
Earnings
Star Bulk Carriers reports Q3 EPS 18c, two estimates 17c »

Reports Q3 voyage revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRNY

Kearny Financial

$14.11

-0.08 (-0.56%)

17:01
11/20/19
11/20
17:01
11/20/19
17:01
Hot Stocks
Kearny Financial raises quarterly dividend to 7c from 6c per share »

Payable on December 20 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$16.00

-1.19 (-6.92%)

16:48
11/20/19
11/20
16:48
11/20/19
16:48
Hot Stocks
Breaking Hot Stocks news story on L Brands »

L Brands up 5.8% or 92c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

16:47
11/20/19
11/20
16:47
11/20/19
16:47
Periodicals
LVMH, Tiffany said to be in talks, Bloomberg says »

LVMH (LVMUY) is said to…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

LB

L Brands

$16.00

-1.19 (-6.92%)

16:46
11/20/19
11/20
16:46
11/20/19
16:46
Hot Stocks
L Brands backs FY19 free cash flow forecast at ~$750M »

Cuts FY19 SSS view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

UBER

Uber

$28.02

0.99 (3.66%)

16:43
11/20/19
11/20
16:43
11/20/19
16:43
Hot Stocks
Uber CEO Dara Khosrowshahi buys almost $7M in company shares »

Uber CEO Dara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

AVVIY

Aviva

$0.00

(0.00%)

16:42
11/20/19
11/20
16:42
11/20/19
16:42
Downgrade
Aviva rating change  »

Aviva downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLLGY

Hella KGaA Hueck

$0.00

(0.00%)

16:42
11/20/19
11/20
16:42
11/20/19
16:42
Upgrade
Hella KGaA Hueck rating change  »

Hella GmbH upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEG

Key Energy

$0.30

0.0095 (3.32%)

16:40
11/20/19
11/20
16:40
11/20/19
16:40
Hot Stocks
Key Energy receives notice from NYSE regarding continued listing requirements »

Key Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLLGY

Hella KGaA Hueck

$0.00

(0.00%)

16:40
11/20/19
11/20
16:40
11/20/19
16:40
Upgrade
Hella KGaA Hueck rating change  »

Hella KGaA Hueck upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGHC

National General

$20.47

-0.43 (-2.06%)

16:39
11/20/19
11/20
16:39
11/20/19
16:39
Hot Stocks
National General approved to sell its Accident Health and Care Sweden unit »

National General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$126.37

15.51 (13.99%)

, LOW

Lowe's

$117.84

4.43 (3.91%)

16:38
11/20/19
11/20
16:38
11/20/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

Stocks were slumping a…

TGT

Target

$126.37

15.51 (13.99%)

LOW

Lowe's

$117.84

4.43 (3.91%)

GM

General Motors

$35.26

-1.13 (-3.11%)

FCAU

Fiat Chrysler

$15.00

-0.585 (-3.75%)

KNSA

Kiniksa

$8.95

1.97 (28.22%)

ALNY

Alnylam

$108.26

10.27 (10.48%)

URBN

Urban Outfitters

$24.41

-4.32 (-15.04%)

PDD

Pinduoduo

$31.37

-9.34 (-22.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 03

    Dec

  • 05

    Dec

  • 07

    Dec

  • 04

    Feb

TUWOY

Tullow Oil

$0.00

(0.00%)

16:37
11/20/19
11/20
16:37
11/20/19
16:37
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,126.21

1.26 (0.11%)

16:36
11/20/19
11/20
16:36
11/20/19
16:36
Hot Stocks
Markel executive chairman Alan Kirshner to retire »

Markel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$236.41

-1.66 (-0.70%)

, FTAI

Fortress Transportation

$16.72

-0.01 (-0.06%)

16:35
11/20/19
11/20
16:35
11/20/19
16:35
Hot Stocks
Canadian Pacific to acquire Central Maine & Quebec Railway from Fortress »

Canadian Pacific (CP) and…

CP

Canadian Pacific

$236.41

-1.66 (-0.70%)

FTAI

Fortress Transportation

$16.72

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLLS

Cellectis

$13.13

-0.14 (-1.06%)

16:34
11/20/19
11/20
16:34
11/20/19
16:34
Hot Stocks
Cellectis wins patent challenge in Europe for CRISPR-Cas9 gene editing method »

Cellectis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$16.00

-1.19 (-6.92%)

16:34
11/20/19
11/20
16:34
11/20/19
16:34
Hot Stocks
L Brands sees Q4 SSS 'about flat' »

Sees FY19 SSS "About…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

TBNK

Territorial Bancorp

$30.63

-0.31 (-1.00%)

16:34
11/20/19
11/20
16:34
11/20/19
16:34
Hot Stocks
Territorial Bancorp declares special dividend of 50c per share »

Territorial Bancorp has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.